Paper Details

  1. Home
  2. Paper Details

Effects of dabrafenib and erlotinib combination treatment on anaplastic thyroid carcinoma.

Author: ChoiYeon-Sook, JeonMin Ji, KimTae Yong, KimWon Bae, KimWon Gu, KwonHyemi, ShongYoung Kee, YouMi-Hyeon

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Combining dabrafenib (BRAF inhibitor) with erlotinib (EGFR inhibitor) synergistically inhibited proliferation, migration, and induced apoptosis in BRAF-mutated anaplastic thyroid carcinoma (ATC) cells. This combination showed similar efficacy to dabrafenib with trametinib, offering a potential novel treatment regimen for overcoming dabrafenib resistance in ATC patients.
Paper Details　
Original Abstract of the Article :
Dabrafenib is a BRAF kinase inhibitor approved for treatment of BRAF-mutated anaplastic thyroid carcinoma (ATC) in combination with trametinib. Erlotinib is a tyrosine kinase inhibitor of EGF receptor (EGFR). We evaluated effects of dabrafenib and erlotinib combination treatment on ATC cells in vitr...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/35343921

データ提供：米国国立医学図書館（NLM）

A New Approach to Combating Anaplastic Thyroid Carcinoma

The treatment of [anaplastic thyroid carcinoma (ATC)] remains a significant challenge in [oncology]. This study investigates the [synergistic effects] of combining [dabrafenib and erlotinib], two targeted therapies, against [BRAF-mutated ATC cells]. The authors conducted both [in vitro and in vivo studies] to evaluate the combination's impact on cell proliferation, colony formation, apoptosis, and migration. Their findings suggest that [dabrafenib and erlotinib combination] demonstrates [synergistic inhibition] of ATC cell growth and promotes [apoptosis], potentially offering a [novel treatment regimen] for patients with BRAF-mutated ATC.

A Promising Path Through the Desert of Thyroid Cancer

The desert of thyroid cancer can be a challenging landscape for patients, often leading to limited treatment options. This research offers a potential path forward by highlighting the synergistic effects of combining dabrafenib and erlotinib. These findings suggest that this combination therapy could represent a valuable tool for navigating this challenging terrain, offering a beacon of hope for patients facing this aggressive form of cancer.

A New Oasis in the Desert of Thyroid Cancer

This study provides a potential oasis of hope for patients battling anaplastic thyroid carcinoma. By demonstrating the synergistic effects of combining dabrafenib and erlotinib, this research suggests that this combination therapy could offer a more effective and targeted approach to fighting this aggressive form of cancer. These findings encourage continued research into this promising therapeutic strategy, offering a beacon of hope for patients navigating the desert of thyroid cancer.

Dr. Camel's Conclusion

This study provides a promising new avenue for treating anaplastic thyroid carcinoma. The synergistic effects of combining dabrafenib and erlotinib offer a potential breakthrough in the fight against this aggressive cancer. These findings encourage further research and exploration of this combination therapy as a valuable tool for navigating the desert of thyroid cancer and improving patient outcomes.

Date :
  1. Date Completed 2022-05-11
  2. Date Revised 2022-05-24
Further Info :

Pubmed ID

35343921

DOI: Digital Object Identifier

ERC-22-0022

Related Literature

Article Analysis
・Effects of erlotinib・Effects of dabrafenib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.